• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$8.45 $0.34 (4.19%)

REAL-TIME: Last trade at

Progenics Pharmaceuticals, Inc...

NASDAQ:PGNX

Jump to this page for:

Related Resources

Progenics Pharmaceuticals reports Q1 EPS (39c), consensus (33c)

5/8/2012 by Theflyonthewall.com

Progenics Pharmaceuticals to Host Conference Call to Review First Quarter Financial Results on May

5/4/2012 by NASDAQ

FDA extends review of Salix, Progenics drug

4/25/2012 by Product Design and Development

Salix (SLXP), Progenics (PGNX) Get FDA PDUFA Extension Date for RELISTOR

4/25/2012 by StreetInsider.com

Salix and Progenics' Relistor sNDA goal date extended by FDA to July 27

4/25/2012 by Theflyonthewall.com

Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012

4/25/2012 by Business Wire

The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals

4/24/2012 by PR Newswire

The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals - Press Releases

4/24/2012 by Zacks Investment Research

FDA Response To Progenics' Supplemental NDA Application Looms

4/20/2012 by Seeking Alpha

Dendreon Will Plummet On DCVax Approval

4/17/2012 by Seeking Alpha

4 Biotech Stocks To Consider Beyond Dendreon

4/3/2012 by Seeking Alpha

Progenics Pharmaceuticals to Participate in Investor Conferences

3/29/2012 by NASDAQ

Progenics Pharmaceuticals to Participate in Investor Conferences

3/29/2012 by GlobeNewswire

Progenics Pharmaceuticals - PGNX - Q4 and year end 2011 results of operations

3/15/2012 by FutureSource.com

Progenics Pharmaceuticals, Inc. (PGNX) Misses Q4 EPS by 3c; Founder Maddon to Retire

3/15/2012 by StreetInsider.com

Progenics Pharmaceuticals announces retirement of founder Paul J. Maddon

3/15/2012 by Theflyonthewall.com

Progenics Pharmaceuticals reports Q4 EPS (32c), consensus (29c)

3/15/2012 by Theflyonthewall.com

Progenics Pharmaceuticals Announces Retirement of Founder Paul J. Maddon

3/15/2012 by GlobeNewswire

Progenics Pharmaceuticals to Host Conference Call to Review Fourth Quarter and Year-End 2011 Financ

3/13/2012 by NASDAQ

Progenics Pharmaceuticals to Host Conference Call to Review Fourth Quarter and Year-End 2011 Financial Results on March 15

3/13/2012 by GlobeNewswire

Progenics Pharmaceuticals management to meet with Lazard Capital

2/23/2012 by Theflyonthewall.com

Take Two : Progenics Pharma

2/21/2012 by RTTNews

Progenics Should Outperform The Market In The Short Term

2/15/2012 by Seeking Alpha

The Salix Story Keeps Improving (SLXP, FRX, ENDP, NKTR)

1/18/2012 by Investopedia

Needham & Company Reiterates a 'Buy' on Progenics Pharmaceuticals (PGNX);

1/6/2012 by StreetInsider.com

7 Stocks Hitting New 52-Week Highs

12/21/2011 by TheStreet.com

2-Star Stocks Poised to Plunge: Progenics?

12/21/2011 by The Motley Fool

Salix Pharmaceuticals Ltd. (SLXP) Rose To An 11-Month High On Study Results

12/21/2011 by RTTNews

Progenics Rises as Constipation Drug Shows Benefits in Trial

12/20/2011 by Bloomberg.com

CVS, Juniper, Progenics, Pulte Group, Sprint: U.S. Equity Movers

12/20/2011 by Bloomberg.com

Needham Upgrades Progenics Pharma (PGNX) to Buy

12/20/2011 by StreetInsider.com

Progenics Pharmaceuticals upgraded to Buy from Hold at Needham

12/20/2011 by Theflyonthewall.com

Salix, Progenics announce positive study results

12/20/2011 by Product Design and Development

Salix Pharmaceuticals Shares Popped: What You Need to Know

12/20/2011 by The Motley Fool

Salix reports positive Phase III results for constipation drug

12/20/2011 by Triangle Business Journal - Raleigh NC

Morning Movers (MSHL, CSIQ, TRGT,PGNX, CIE)

12/20/2011 by 24/7 Wall Street

Pre-market Movers For Dec 20 (T, JEF, NAV, CVS, SLXP, CSIQ, GIS, AZN, TRGT)

12/20/2011 by RTTNews

Salix (SLXP) and Progenics (PGNX) Announce Positive Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic

12/20/2011 by StreetInsider.com

Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation

12/20/2011 by Business Wire

Progenics Pharmaceuticals Lures Call Players in the Options Pits

12/7/2011 by Schaeffer's Daily Market Blog
See More Articles...